Ex vivo and in vivo inhibition of human rhinovirus replication by a new pseudosubstrate of viral 2A protease

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 691-704

  Falah, Nisrine ^a   Violot, Sébastien ^b,c   Décimo, Didier ^d   Berri, Fatma ^a   Foucault Grunenwald, Marie Laure ^a   Ohlmann, Théophile ^d   Schuffenecker, Isabelle ^e   Morfin, Florence ^e   Lina, Bruno ^a,e   Riteau, Béatrice ^a,f   Cortay, Jean Claude ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^d UNIVERSITÉ DE LYON   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYSTEINE PROTEINASE; LVLQTM PEPTIDE; UNCLASSIFIED DRUG; VIRAL 2A CYSTEINE PROTEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; IN VIVO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHINOVIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; PICORNAVIRIDAE INFECTIONS; PROTEIN BINDING; RHINOVIRUS; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN RHINOVIRUS SP.; MUS;

EID: 84856934021     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05263-11     Document Type: Article

References (35)

1. Badorff C, et al. 2000. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J. Biol. Chem. 275:11191-11197.
2. Bartlett NW, et al. 2008. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 14:199-204.
3. Belov GA, et al. 2000. Early alteration of nucleocytoplasmic traffic induced by some RNA viruses. Virology 275:244-248.
4. Deszcz L, Cencic R, Sousa C, Kuechler E, Skern T. 2006. An antiviral peptide inhibitor that is active against picornavirus 2A proteinases but not cellular caspases. J. Virol. 80:9619-9627.
5. Deszcz L, Seipelt J, Vassilieva E, Roetzer A, Kuechler E. 2004. Antiviral activity of caspase inhibitors: effect on picornaviral 2A proteinase. FEBS Lett. 560:51-55.
6. Fromont-Racine M, Rain JC, Legrain P. 1997. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat. Genet. 16:277-282.
7. Garcia-Calvo M, et al. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273: 32608-32613.
8. Gouet P, Robert X, Courcelle E. 2003. ESPript/ENDscript: extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res. 31:3320-3323.
9. Gustin KE, Sarnow P. 2002. Inhibition of nuclear import and alteration of nuclear pore complex composition by rhinovirus. J. Virol. 76: 8787-8796.
10. Joachims M, Van Breugel PC, Lloyd RE. 1999. Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J. Virol. 73:718-727.
11. Jurgens CK, et al. 2006. 2Apro is a multifunctional protein that regulates the stability, translation and replication of poliovirus RNA. Virology 345: 346-357.
12. Kempf BJ, Barton DJ. 2008. Poliovirus 2A(Pro) increases viral mRNA and polysome stability coordinately in time with cleavage of eIF4G. J. Virol. 82:5847-5859.
13. Khoufache K, et al. 2009. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gammadependent pathway. J. Immunol. 182:7795-7802.
14. Kistler A, et al. 2007. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J. Infect. Dis. 196:817-825.
15. Konig H, Rosenwirth B. 1988. Purification and partial characterization of poliovirus protease 2A by means of a functional assay. J. Virol. 62: 1243-1250.
16. Laine P, Savolainen C, Blomqvist S, Hovi T. 2005. Phylogenetic analysis of human rhinovirus capsid protein VP1 and 2A protease coding sequences confirms shared genus-like relationships with human enteroviruses. J. Gen. Virol. 86:697-706.
17. Lamphear BJ, et al. 1993. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human coxsackievirus and rhinovirus. J. Biol. Chem. 268:19200-19203.
18. Molla A, Hellen CU, Wimmer E. 1993. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J. Virol. 67:4688-4695.
19. Ohlmann T, Rau M, Pain VM, Morley SJ. 1996. The C-terminal domain of eukaryotic protein synthesis initiation factor (eIF) 4G is sufficient to support cap-independent translation in the absence of eIF4E. EMBO J. 15:1371-1382.
20. Otto HH, Schirmeister T. 1997. Cysteine proteases and their inhibitors. Chem. Rev. 97:133-172.
21. Palmenberg AC, et al. 2009. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 324:55-59.
22. Papi A, et al. 2006. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173:1114-1121.
23. Park N, Katikaneni P, Skern T, Gustin KE. 2008. Differential targeting of nuclear pore complex proteins in poliovirus-infected cells. J. Virol. 82: 1647-1655.
24. Petersen JF, et al. 1999. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. EMBO J. 18:5463-5475.
25. Prevot D, et al. 2003. Characterization of a novel RNA-binding region of eIF4GI critical for ribosomal scanning. EMBO J. 22:1909-1921.
26. Reed LJ, Muench H. 1938. A simple method of estimating 50 per cent endpoints. Am. J. Hyg. 27:493-497.
27. Sommergruber W, et al. 1994. 2A proteinases of coxsackie- and rhinovirus cleave peptides derived from eIF-4 gamma via a common recognition motif. Virology 198:741-745.
28. Sommergruber W, et al. 1992. Cleavage specificity on synthetic peptide substrates of human rhinovirus 2 proteinase 2A. J. Biol. Chem. 267: 22639-22644.
29. Soto Rifo R, Ricci EP, Decimo D, Moncorge O, Ohlmann T. 2007. Back to basics: the untreated rabbit reticulocyte lysate as a competitive system to recapitulate cap/poly(A) synergy and the selective advantage of IRESdriven translation. Nucleic Acids Res. 35:e121.
30. Studier FW. 2005. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 41:207-234.
31. Timmer T, et al. 1999. A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3. Eur. J. Hum. Genet. 7:478-486.
32. van Gunsteren WF. 1996. Biomolecular simulation: the GROMOS96 manual and user guide. vdf, Zürich, Switzerland.
33. Ventoso I, Barco A, Carrasco L. 1999. Genetic selection of poliovirus 2Apro-binding peptides. J. Virol. 73:814-818.
34. Vojtek AB, Hollenberg SM. 1995. Ras-Raf interaction: two-hybrid analysis. Methods Enzymol. 255:331-342.
35. Zunszain PA, et al. 2010. Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate. J. Mol. Biol. 395:375-389.